Overview

Study of Individualized Amonafide to Treat Prostate Cancer

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted on individual metabolism).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Xanthus Pharmaceuticals, Inc.
Treatments:
Amonafide